{
  "id": 20855493,
  "title": "HIV-1 Mutational Bias Shapes the Supply of Drug Resistance Mutations",
  "url": "https://urgent.news/2026/11/19/hiv-1-mutational-bias-shapes-the-supply-of-drug-resistance-mutations",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-19T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.11.19.767678v1?rss=1"
  },
  "original_language": "en",
  "account": "The research article, \"HIV-1 Mutational Bias Shapes the Supply of Drug Resistance Mutations,\" explores the crucial role that HIV-1's mutational bias plays in the emergence of drug resistance. Understanding the factors that contribute to the development of durable HIV-1 therapeutics necessitates a comprehensive comprehension of not just which mutations confer resistance, but also how easily those mutations arise. Although prior studies have examined the impact of individual mutations on viral fitness and drug or immune escape, the influence of mutational bias on HIV-1's evolutionary pathways has remained largely unquantified. In this study, the authors introduce a novel tool, the HIV-1 Mutation Rate Atlas (MRA), constructed using a dataset of empirical measurements of single-cycle HIV-1 mutation accumulation in the absence of selection pressure. This tool leverages error-corrected long-read sequencing to estimate the mutation rate at every genomic position to each possible nucleotide, thereby providing a detailed map of amino acid mutability across the genome. By utilizing the MRA, the researchers demonstrate that mutation rate biases can accurately predict the frequencies of HIV-1 drug resistance variants across different patients. These findings not only highlight the significant role of mutational biases in shaping HIV-1's evolutionary outcomes but also offer a promising framework for predicting and potentially managing the evolution and spread of drug resistance in HIV-1 infections.",
  "summary": "The development of durable HIV-1 therapeutics requires understanding not only which mutations confer resistance, but also how readily those mutations arise. Prior work has characterized the effects of individual mutations on viral fitness and drug or immune escape; however, the contribution of mutational bias to HIV-1 evolutionary pathways remains largely unquantified. Here, we report and provide…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}